Suzhou Zelgen Biopharmaceuticals Co Ltd (688266) — Net Asset Quality Index
Suzhou Zelgen Biopharmaceuticals Co Ltd (688266) has a Net Asset Quality Index of 38.1% as of September 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥3.01 Billion minus total liabilities of CN¥1.86 Billion yields net assets of CN¥1.15 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Read Suzhou Zelgen Biopharmaceuticals Co Ltd (688266) financial obligations for a breakdown of total debt and financial obligations.
Quality Index
Net Assets
Total Assets
Total Liabilities
Suzhou Zelgen Biopharmaceuticals Co Ltd Net Asset Quality Index Over Time (2016–2024)
This chart shows how Suzhou Zelgen Biopharmaceuticals Co Ltd's Net Asset Quality Index has evolved across 9 annual periods from 2016 to 2024. As of September 2025, the index stands at 38.1%, representing net assets of CN¥1.15 Billion against total assets of CN¥3.01 Billion CNY. For live market cap and overall valuation, see Suzhou Zelgen Biopharmaceuticals Co Ltd market cap and net worth.
Annual Net Asset Quality Index for Suzhou Zelgen Biopharmaceuticals Co Ltd (2016–2024)
The table below presents the year-by-year Net Asset Quality Index for Suzhou Zelgen Biopharmaceuticals Co Ltd from 2016 to 2024, covering 9 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. Check how strategically is Suzhou Zelgen Biopharmaceuticals Co Ltd's equity deployed to assess the company's strategic physical and investment asset allocation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 41.7% | CN¥1.25 Billion | CN¥3.00 Billion | CN¥1.75 Billion | ▼ -15.3 pp |
| 2023 | 57.0% | CN¥1.64 Billion | CN¥2.89 Billion | CN¥1.24 Billion | ▲ +9.8 pp |
| 2022 | 47.2% | CN¥787.49 Million | CN¥1.67 Billion | CN¥880.82 Million | ▼ -24.6 pp |
| 2021 | 71.8% | CN¥1.25 Billion | CN¥1.75 Billion | CN¥492.88 Million | ▼ -14.1 pp |
| 2020 | 85.9% | CN¥1.69 Billion | CN¥1.97 Billion | CN¥278.69 Million | ▲ +62.8 pp |
| 2019 | 23.0% | CN¥73.75 Million | CN¥320.27 Million | CN¥246.52 Million | ▼ -38.9 pp |
| 2018 | 61.9% | CN¥281.64 Million | CN¥454.88 Million | CN¥173.24 Million | ▲ +12.5 pp |
| 2017 | 49.5% | CN¥73.02 Million | CN¥147.63 Million | CN¥74.61 Million | ▼ -30.3 pp |
| 2016 | 79.8% | CN¥109.44 Million | CN¥137.20 Million | CN¥27.76 Million | — |